Case Study
Innovative Insights: A Diagnostics Company’s Road to Excellence
Navigating Growth: A Diagnostic Company's Journey into the U.S. Market
The diagnostics company began its U.S. expansion by partnering with a small North American tribe. Although this approach enabled rapid decisions and zero initial cost, the company soon found itself under a lot of stress. The solution adopted was an equity investment, followed by an evolutionary, hybrid strategy involving investments in small, single-product companies to broaden the portfolio and increase visibility.
The immediate advantage was rapid decision-making within a family structure, with the partner taking charge of all costs, offering a start-up with no initial investment.
To remedy the situation, the company opted for an equity investment, demonstrating its willingness and seeking greater control, visibility and financial resources.
This diagnostics company began its expansion in the USA by teaming up with a small North American tribe. The immediate advantage was rapid decision-making within a family structure, with the partner assuming full responsibility for costs – an approach often sought by French SMEs looking for distributors or sales representatives. However, this model has revealed some major drawbacks, notably the undersizing of the company at all levels, and the lack of experience in the specific sector.
The lack of control and visibility over activities, being dependent on the North American partner, accentuated the challenges. To remedy this situation, the company took a shareholding, demonstrating its goodwill while seeking to contribute resources and gain greater control and visibility. This strategy paved the way for an evolutionary and hybrid approach.
The company decided to diversify its product portfolio through external growth, targeting small, single-product companies. This approach has enabled the company to position itself more attractively for larger partners, to spread risk and to have promising products carried by more mature products. It has also helped the company achieve critical mass, boosting its visibility and competitive position in the US diagnostics market.